A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-Related Symptoms Are Inadequately Controlled by Somatostatin Analogues.

Trial Profile

A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-Related Symptoms Are Inadequately Controlled by Somatostatin Analogues.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Pasireotide (Primary) ; Octreotide
  • Indications Carcinoid tumour
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 10 Aug 2017 This trial has been discontinued in Belgium, as per European Clinical Trials Database record.
    • 31 May 2013 Primary endpoint 'Symptom-rate' has not been met.
    • 31 May 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top